Scarica l'app Stockscreener
297.83
1.08%
3.18
Dopo l'orario di chiusura:
287.77
-10.06
-3.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$294.65
Aprire:
$297.19
Volume 24 ore:
1.31M
Relative Volume:
0.87
Capitalizzazione di mercato:
$57.73B
Reddito:
$310.23B
Utile/perdita netta:
$1.69B
Rapporto P/E:
34.55
EPS:
8.62
Flusso di cassa netto:
$3.58B
1 W Prestazione:
-0.78%
1M Prestazione:
+1.82%
6M Prestazione:
+23.64%
1 anno Prestazione:
+32.15%
Intervallo 1D:
$293.81
$298.21
Intervallo di 1 settimana:
$293.55
$301.22
Portata 52W:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Nome
Cencora Inc
Settore
Industria
Telefono
610-727-7000
Indirizzo
1 WEST FIRST AVENUE, CONSHOHOCKEN
Confronta COR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
297.83 | 58.18B | 310.23B | 1.69B | 3.58B | 8.62 |
|
MCK
Mckesson Corporation
|
715.74 | 90.83B | 359.05B | 3.30B | 5.23B | 25.83 |
|
CAH
Cardinal Health Inc
|
161.11 | 39.21B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
69.32 | 9.27B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.751 | 642.10M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Ripresa | Mizuho | Outperform |
| 2024-09-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-03 | Iniziato | Barclays | Overweight |
| 2023-12-14 | Iniziato | Wells Fargo | Equal Weight |
| 2023-03-31 | Iniziato | Citigroup | Buy |
| 2023-01-31 | Ripresa | Evercore ISI | Outperform |
| 2022-10-11 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Ripresa | Evercore ISI | In-line |
| 2021-02-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-01-06 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Iniziato | Mizuho | Neutral |
| 2020-08-06 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Iniziato | Barclays | Underweight |
| 2020-06-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Ripresa | Credit Suisse | Outperform |
| 2020-04-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-11 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Iniziato | Deutsche Bank | Hold |
| 2019-07-10 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Iniziato | Guggenheim | Buy |
| 2019-04-10 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Iniziato | UBS | Buy |
| 2018-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2018-10-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Iniziato | Berenberg | Buy |
| 2018-07-17 | Ripresa | Stifel | Hold |
| 2018-04-09 | Iniziato | MoffettNathanson | Buy |
| 2018-03-12 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Iniziato | JP Morgan | Neutral |
| 2017-09-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Cencora Inc Borsa (COR) Ultime notizie
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - BioSpace
Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion - simplywall.st
Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com Nigeria
Lobbying Update: $20,000 of CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) lobbying was just disclosed - Quiver Quantitative
Here's What to Expect From Cencora's Next Earnings Report - MSN
Cencora, Inc. (COR): If It Was Down, I’d Say “Double Down And Buy,” Says Jim Cramer - Insider Monkey
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Here's Why You Should Add Cencora Stock to Your Portfolio Now - Yahoo Finance
Cencora to Announce Q3 2025 Results on August 6 with Live Webcast and Conference Call - MSN
Fund Update: FERGUSON WELLMAN CAPITAL MANAGEMENT, INC added 79,430 shares of CENCORA ($COR) to their portfolio - Quiver Quantitative
Here's What To Expect From Cencora's Next Earnings Report - Barchart.com
Cencora Enhances Receivables Purchase Agreement for Liquidity - TipRanks
Cencora Trading Volume Drops 40.8% to $385 Million Ranking 278th in Market - AInvest
Mizuho maintains Cencora stock rating on strong Walgreens data - Investing.com
Cencora's Trading Volume Drops 44.5% to 2.74 Billion, Ranks 340th Despite Two-Day Gain - AInvest
Cencora's Insider Exodus: Risk or Opportunity? - AInvest
Insider Sell: Silvana Battaglia Sells Shares of Cencora Inc (COR) - GuruFocus
Three fund managers share picks for tariff-resistant U.S. stocks - The Globe and Mail
$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today - Benzinga
Cencora Welcomes Lori J. Ryerkerk to Board of Directors - MSN
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cardinal Health boosts profit view banking on specialty drugs unit growth - Reuters
Is Cencora Stock Outperforming The Dow? - Barchart.com
Is Cencora Stock Outperforming the Dow? - The Globe and Mail
Cencora, Inc. (COR) Enhances Financial Flexibility with Amended Credit Agreements - GuruFocus
Cencora Enhances Financial Flexibility with Credit Amendments - TipRanks
Cencora IncIncreases Revolving Credit Facility To $4.5 Billion - MarketScreener
Cardinal Health, Cencora upgraded at Wells Fargo on industry outlook - MSN
Cravath Advises on €1B Cencora Notes Offering - Lawyer Monthly
Mizuho Adjusts Price Target on Cencora to $316 From $315, Maintains Outperform Rating - marketscreener.com
Cencora (NYSE:COR) Upgraded by Wells Fargo & Company to “Overweight” Rating - Defense World
Wells Fargo Upgrades Cencora (COR) Stock to Overweight, Lifts PT - MSN
Cencora (COR) Receives Upgrade as Analysts Set New Price Target - GuruFocus
Wells Fargo Upgrades Cencora (COR) - Nasdaq
Wells Fargo upgrades Cencora stock rating, raises price target to $337 - Investing.com Nigeria
Wells Fargo Upgrades Cencora (COR) with Raised Price Target | COR Stock News - GuruFocus
Assessing Cencora: Insights From 6 Financial Analysts - Benzinga
Cencora (COR) Receives Upgrade as Analysts Set New Price Target | COR Stock News - GuruFocus
Wells Fargo Elevates Cencora (COR) to Overweight with Raised Price Target | COR Stock News - GuruFocus
Top Cencora Executive Cashes In on Significant Stock Sale! - TipRanks
Insider Sell Alert: Lazarus Krikorian Sells 3,000 Shares of Cenc - GuruFocus
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is Zacks Research’s Estimate for Cencora Q2 Earnings? - Defense World
Cencora, Inc. Declares Quarterly Cash Dividend, Payable on June 2, 2025 - marketscreener.com
What is Zacks Research’s Estimate for Cencora Q3 Earnings? - Defense World
Nephron Research Adjusts Cencora Price Target to $335 From $325 - marketscreener.com
Cencora, Inc. (COR) Announces Board Changes: New Appointment and Resignation - GuruFocus
Cencora appoints new board member to boost growth By Investing.com - Investing.com South Africa
Cencora Inc Azioni (COR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):